Glaukos Shares Surge on Triple Dose of Positive News
Published on 11/01/2025 at 20:31 | Editorial boerse-global.de
Glaukos Corporation has ignited investor enthusiasm with a powerful trifecta of developments, propelling its stock to impressive gains. The equity advanced nearly 18% within a single week, fueled by record-breaking financial results, an upward revision of its financial outlook, and a significant regulatory approval from the U.S. Food and Drug Administration. The central question for the market is whether this powerful momentum is sustainable.
A pivotal development occurred on October 20, when the FDA granted approval for Epioxa
. This treatment is recognized as the first and only incision-free therapy for keratoconus. The Read more...
Disclaimer...
en | US3773221029 | GLAUKOS | boerse | 68315763 |
